Literature DB >> 15329424

Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.

Mary B Leonard1, Harold I Feldman, Justine Shults, Babette S Zemel, Bethany J Foster, Virginia A Stallings.   

Abstract

BACKGROUND: Glucocorticoids suppress bone formation, impair growth, and induce obesity. We determined the effects of long-term treatment with glucocorticoids on bone mineral content in children with glucocorticoid-sensitive nephrotic syndrome, a disorder with minimal known independent effects on bone.
METHODS: We performed dual-energy x-ray absorptiometry of the whole body and spine in 60 children and adolescents with the nephrotic syndrome and 195 control subjects. We used linear regression analysis of log-transformed values to compare the bone mineral content in patients with that in controls.
RESULTS: Patients had received an average of 23,000 mg of glucocorticoids and were shorter (P=0.008) and had a greater body-mass index (P<0.001) than controls. The bone mineral content of the spine, adjusted for bone area, age, sex, degree of maturation (Tanner stage), and race, did not differ significantly between patients and controls (ratio, 0.99; 95 percent confidence interval, 0.96 to 1.02; P=0.51). After adjustment for the z score for body-mass index, the bone mineral content of the spine was significantly lower in patients than in controls (0.96; 95 percent confidence interval, 0.92 to 0.99; P=0.01). Whole-body bone mineral content, adjusted for height, age, sex, degree of maturation, and race, was significantly higher in patients than in controls (ratio, 1.11; 95 percent confidence interval, 1.05 to 1.18; P<0.001); however, the addition of the z score for body-mass index to the model eliminated the association with the nephrotic syndrome (ratio, 0.99; 95 percent confidence interval, 0.94 to 1.03; P=0.55).
CONCLUSIONS: Intermittent treatment with high-dose glucocorticoids during growth does not appear to be associated with deficits in the bone mineral content of the spine or whole body relative to age, bone size, sex, and degree of maturation. Glucocorticoid-induced increases in body-mass index were associated with increased whole-body bone mineral content and maintenance of the bone mineral content of the spine. Copyright 2004 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329424     DOI: 10.1056/NEJMoa040367

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

1.  Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome.

Authors:  Anne Marie Sbrocchi; Frank Rauch; MaryAnn Matzinger; Janusz Feber; Leanne M Ward
Journal:  Pediatr Nephrol       Date:  2010-10-05       Impact factor: 3.714

2.  Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation.

Authors:  Sogol Mostoufi-Moab; Jill P Ginsberg; Nancy Bunin; Babette S Zemel; Justine Shults; Meena Thayu; Mary B Leonard
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

3.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

Review 4.  Assessment of bone mass following renal transplantation in children.

Authors:  Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

Review 5.  Clinical research in pediatric nephrology: state of the art.

Authors:  Gregory H Gorman; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

6.  Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.

Authors:  Bethany J Foster; Justine Shults; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

7.  Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.

Authors:  J Feber; I Gaboury; A Ni; N Alos; S Arora; L Bell; T Blydt-Hansen; C Clarson; G Filler; J Hay; D Hebert; B Lentle; M Matzinger; J Midgley; D Moher; M Pinsk; F Rauch; C Rodd; N Shenouda; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2011-04-15       Impact factor: 4.507

8.  The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.

Authors:  Sushmita Banerjee; Surupa Basu; Ananda Sen; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2017-07-19       Impact factor: 3.714

9.  Glucocorticoid-induced osteoporosis: how best to avoid fractures.

Authors:  Mark S Cooper
Journal:  Ther Adv Chronic Dis       Date:  2010-01       Impact factor: 5.091

10.  Variation in Preventive Care in Children Receiving Chronic Glucocorticoid Therapy.

Authors:  Matthew L Basiaga; Evanette K Burrows; Michelle R Denburg; Kevin E Meyers; Andrew B Grossman; Petar Mamula; Robert W Grundmeier; Jon M Burnham
Journal:  J Pediatr       Date:  2016-09-09       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.